Trials / Completed
CompletedNCT05565742
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 320 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3819469 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2022-10-20
- Primary completion
- 2023-10-23
- Completion
- 2024-10-17
- First posted
- 2022-10-04
- Last updated
- 2025-05-28
- Results posted
- 2025-05-28
Locations
80 sites across 10 countries: United States, Argentina, China, Denmark, Germany, Japan, Mexico, Netherlands, Romania, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05565742. Inclusion in this directory is not an endorsement.